Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)

BACKGROUND: Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein–mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Michael Gibson, C., Korjian, Serge, Tricoci, Pierluigi, Daaboul, Yazan, Yee, Megan, Jain, Purva, Alexander, John H., Steg, P. Gabriel, Lincoff, A. Michael, Kastelein, John J.P., Mehran, Roxana, D’Andrea, Denise M., Deckelbaum, Lawrence I., Merkely, Bela, Zarebinski, Maciej, Ophuis, Ton Oude, Harrington, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2016
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5147036/
https://ncbi.nlm.nih.gov/pubmed/27881559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.116.025687
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados